Publications by authors named "Chikuma Hamada"

Claim this Profile
R
Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study.
Yoshiya Tanaka, Hideto Kameda, Kazuyoshi Saito, Yuko Kaneko, Eiichi Tanaka, Chikuma Hamada

Mod Rheumatol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performance of randomization-based causal methods with and without integrating external data sources for adjusting overall survival in case of extensive treatment switches in placebo-controlled randomized oncology phase 3 trials.
Shogo Nomura, Tomohiro Shinozaki, Chikuma Hamada

J Biopharm Stat· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sample size determination for the current strategy in oncology Phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework.
Shogo Nomura, Akihiro Hirakawa, Chikuma Hamada

J Biopharm Stat· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two-stage approach based on zone and dose findings for two-agent combination Phase I/II trials.
Fumiya Shimamura, Chikuma Hamada, Shigeyuki Matsui, Akihiro Hirakawa

J Biopharm Stat· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study.
Naohiro Tomita, Katsuyuki Kunieda, Atsuyuki Maeda, Chikuma Hamada, Takeharu Yamanaka

Br J Cancer· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Bayesian hierarchal modeling approach to shortening phase I/II trials of anticancer drug combinations.
Shinjo Yada, Chikuma Hamada

Pharm Stat· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer.
Shuhei Mayanagi, Kosuke Kashiwabara, Michitaka Honda, Koji Oba, Toru Aoyama, Chikuma Hamada

Dis Colon Rectum· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study.
Yoshiya Tanaka, Hideto Kameda, Kazuyoshi Saito, Yuko Kaneko, Eiichi Tanaka, Chikuma Hamada

Arthritis Res Ther· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Signatures of Mucinous and Poorly Differentiated Subtypes of Colorectal Adenocarcinomas by a Propensity Score Analysis of an Independent Patient Database from Three Phase III Trials.
Mitsuro Kanda, Koji Oba, Toru Aoyama, Kosuke Kashiwabara, Shuhei Mayanagi, Chikuma Hamada

Dis Colon Rectum· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of Tegafur-Uracil on Survival in T Categories as Defined in the Eighth Edition of the TNM Classification: An Exploratory Analysis of Postoperative Adjuvant Tegafur-Uracil on Survival in Patients with Adenocarcinoma of the Lung.
Masahiro Tsuboi, Chikuma Hamada, Harubumi Kato, Mitsuo Ohta

Chemotherapy· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Questionnaire Survey From the Viewpoint of Concordance in Patient and Physician Satisfaction Concerning Hypertensive Treatment in Elderly Patients　- Patients Voice Study.
Yoshiyuki Ikeda, Takeshi Sasaki, So Kuwahata, Masakazu Imamura, Kanyo Tanoue, Chikuma Hamada

Circ J· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statistical analysis for toxicity studies.
Chikuma Hamada

J Toxicol Pathol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adaptive phase I/II clinical trials for drug combination assessment in oncology using the outcomes of each cycle.
Shinjo Yada, Chikuma Hamada

Pharm Stat· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical impact of tumor location on the colon cancer survival and recurrence: analyses of pooled data from three large phase III randomized clinical trials.
Toru Aoyama, Kosuke Kashiwabara, Koji Oba, Michitaka Honda, Sotaro Sadahiro, Chikuma Hamada

Cancer Med· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of a prognostic nomogram for colorectal cancer after radical resection based on individual patient data from three large-scale phase III trials.
Michitaka Honda, Koji Oba, Takashi Akiyoshi, Hiromichi Maeda, Kosuke Kashiwabara, Chikuma Hamada

Oncotarget· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adaptive Seamless Design for Establishing Pharmacokinetic and Efficacy Equivalence in Developing Biosimilars.
Ryuji Uozumi, Chikuma Hamada

Ther Innov Regul Sci· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Proposal for Progression-Free Survival Assessment in Patients with Early Progressive Cancer.
Takanori Tanase, Chikuma Hamada, Takayuki Yoshino, Atsushi Ohtsu

Anticancer Res· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials.
Hiromichi Maeda, Kosuke Kashiwabara, Toru Aoyama, Koji Oba, Michitaka Honda, Chikuma Hamada

J Cancer· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analyses of drug combinations using missing data shortens trial periods in phase I/II oncology trials.
Shinjo Yada, Chikuma Hamada

Contemp Clin Trials Commun· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.
Takeshi Suto, Megumi Ishiguro, Chikuma Hamada, Katsuyuki Kunieda, Hiroyuki Masuko

Int J Clin Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin.
Kazuhiro Nishikawa, Yasuhide Yamada, Kenji Ishido, Masahiro Gotoh, Hideaki Bando, Chikuma Hamada

Gastric Cancer· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of postoperative complications on the colorectal cancer survival and recurrence: analyses of pooled individual patients' data from three large phase III randomized trials.
Toru Aoyama, Koji Oba, Michitaka Honda, Sotaro Sadahiro, Chikuma Hamada

Cancer Med· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.
Takeshi Suto, Megumi Ishiguro, Chikuma Hamada, Katsuyuki Kunieda, Hiroyuki Masuko

Int J Clin Oncol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.
Chikuma Hamada, Takuji Okusaka, Takaaki Ikari, Hiroyuki Isayama, Junji Furuse

Br J Cancer· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of Bayesian hierarchical models for phase I/II clinical trials in oncology.
Shinjo Yada, Chikuma Hamada

Pharm Stat· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis